Who are MK0966 / Duration of Treatment: 1 Days's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): parecoxib, valdecoxib, etoricoxib, Cox2 inhibitor (Celecoxib), MK0966; rofecoxib, Oral Vioxx (Rofecoxib).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mk0966-duration-of-treatment-1-days.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

MK0966 / Duration of Treatment: 1 Days — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MK0966 / Duration of Treatment: 1 Days (MK0966 / Duration of Treatment: 1 Days) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 selective inhibitor (coxib). Area: Rheumatology / Pain Management.

phase 3 COX-2 selective inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

MK0966 / Duration of Treatment: 1 Days (MK0966 / Duration of Treatment: 1 Days) — Merck Sharp & Dohme LLC. MK0966 is a selective COX-2 inhibitor that reduces prostaglandin production to decrease inflammation and pain.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MK0966 / Duration of Treatment: 1 Days TARGET	MK0966 / Duration of Treatment: 1 Days	Merck Sharp & Dohme LLC	phase 3	COX-2 selective inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
parecoxib, valdecoxib, etoricoxib	parecoxib, valdecoxib, etoricoxib	Asker & Baerum Hospital	marketed	COX-2 selective inhibitor (coxib)	COX-2 (cyclooxygenase-2)
Cox2 inhibitor (Celecoxib)	Cox2 inhibitor (Celecoxib)	Seoul National University Hospital	marketed	COX-2 selective inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
MK0966; rofecoxib	MK0966; rofecoxib	Merck Sharp & Dohme LLC	marketed	COX-2 selective inhibitor (coxib)	COX-2 (cyclooxygenase-2)
Oral Vioxx (Rofecoxib)	Oral Vioxx (Rofecoxib)	Chinese University of Hong Kong	phase 3	COX-2 selective inhibitor (coxib)	COX-2 (Cyclooxygenase-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 selective inhibitor (coxib) class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Asker & Baerum Hospital · 1 drug in this class
Chinese University of Hong Kong · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MK0966 / Duration of Treatment: 1 Days — Competitive Intelligence Brief. https://druglandscape.com/ci/mk0966-duration-of-treatment-1-days. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab